47,010 Shares in Relay Therapeutics, Inc. (NASDAQ:RLAY) Acquired by Virtu Financial LLC

Virtu Financial LLC bought a new stake in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 47,010 shares of the company’s stock, valued at approximately $333,000.

Several other large investors have also bought and sold shares of RLAY. EverSource Wealth Advisors LLC bought a new position in shares of Relay Therapeutics in the 2nd quarter worth $37,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Relay Therapeutics during the third quarter worth about $63,000. Portland Investment Counsel Inc. acquired a new position in shares of Relay Therapeutics during the 3rd quarter worth about $71,000. Values First Advisors Inc. bought a new stake in shares of Relay Therapeutics in the 3rd quarter valued at about $75,000. Finally, Point72 DIFC Ltd bought a new stake in shares of Relay Therapeutics in the 3rd quarter valued at about $134,000. 96.98% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently issued reports on RLAY shares. Leerink Partners decreased their price objective on shares of Relay Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a report on Wednesday, December 4th. HC Wainwright lowered their price objective on shares of Relay Therapeutics from $20.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday, December 4th. Barclays lifted their target price on Relay Therapeutics from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, September 10th. Oppenheimer lowered Relay Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, September 10th. Finally, Bank of America boosted their price objective on Relay Therapeutics from $20.00 to $24.00 and gave the company a “buy” rating in a research report on Tuesday, September 10th. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $20.50.

Relay Therapeutics Stock Up 2.8 %

Shares of RLAY opened at $4.84 on Tuesday. Relay Therapeutics, Inc. has a twelve month low of $4.25 and a twelve month high of $12.14. The stock has a market capitalization of $810.12 million, a P/E ratio of -1.85 and a beta of 1.59. The company has a 50 day moving average of $5.56 and a 200-day moving average of $6.69.

Relay Therapeutics (NASDAQ:RLAY) last released its earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.14. During the same quarter in the prior year, the company posted ($0.54) earnings per share. Relay Therapeutics’s revenue for the quarter was down 100.0% on a year-over-year basis. On average, sell-side analysts anticipate that Relay Therapeutics, Inc. will post -2.55 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Thomas Catinazzo sold 6,802 shares of the stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $6.06, for a total value of $41,220.12. Following the completion of the sale, the chief financial officer now owns 306,391 shares of the company’s stock, valued at approximately $1,856,729.46. This represents a 2.17 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 4.32% of the stock is owned by corporate insiders.

About Relay Therapeutics

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.